Clicky

Briacell Therapeutics Corp.(BCT)

Description: BriaCell Therapeutics Corp. is an immuno-oncology biotechnology company. The Company is engaged in the research and development of cancer immunotherapy technology. The Company offers BriaVax, an immunotherapy vaccine. The Company is engaged in developing and advancing its BriaVax immunotherapy vaccine for patients with advanced breast cancer. The Company is also engaged in the research and development of its companion diagnostic product, BriaDx. The Company's BriaDx program is focused on analyzing samples obtained from patients previously treated with BriaVax along with co-analysis of previously manufactured vaccine lots. The Company's analysis methods include various technologies, including gene expression profiling by Illumina microarrays and human leukocyte antigen (HLA) typing by a high-resolution method. The Company is focused on understanding the mechanism of action (MoA) of BriaVax.


Keywords: Medicine Biotechnology Cancer Immunology Oncology Immunotherapy Breast Cancer Cancer Immunotherapy Vaccination Gene Expression Antigen Advanced Breast Cancer Microarrays Immuno Oncology Biotechnology Gustav Gaudernack

Home Page: www.briacell.com

BCT Technical Analysis

Bellevue Centre
West Vancouver, BC V7T 2X1
Canada
Phone: 604 921 1810


Officers

Name Title
Dr. William V. Williams M.D. CEO, Pres & Director
Dr. Charles Louis Wiseman FACP, M.D. Founder, Principal Advisor & Member of Scientific Advisory Board
Mr. Gadi Levin B.Com., C.A., CPA, M.B.A., MBA CFO & Corp. Sec.

Exchange: V

Country: CA

Currency: Canadian Dollar (C$)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 2.1248
Price-to-Sales TTM: 0
IPO Date:
Fiscal Year End: July
Full Time Employees: 5
Back to stocks